
SBRT after progression may be a viable option for oligometastatic castrate-resistant prostate cancer (omCRPC) compared to second-line systemic therapy. In the ARTO trial analysis, median progression-free survival (PFS1+PFS2) was 45.9 months for SBRT (Group A), compared to an unreached value in the second-line systemic therapy group (Group B). Overall survival showed no significant difference (HR 0.50, p=0.284). SBRT remains a feasible approach after oligoprogression.
Like
Save
Share